Patents Issued in August 18, 2020
  • Patent number: 10744174
    Abstract: Pharmaceutically effective compositions and methods for topically treating pain due to swelling or inflammation of fascia, tendons, or ligaments in a patient in need of treatment, thereof. The pharmaceutically effective composition consists essentially of: 68.6-29.4 parts by weight of a pharmaceutically acceptable excipient; 40.0-50.0 parts by weight DMSO; 1.0-5.0 parts by weight of an anesthetic, wherein the anesthetic is advantageously characterized as containing only lidocaine; and 1.2-3.2 parts by weight of an anti-inflammatory in 100 parts by weight of the pharmaceutically effective composition. In one embodiment, the anesthetic is advantageously 4.0 parts by weight Lidocaine. In one embodiment, the pharmaceutically acceptable excipient is 48.0 parts by weight, DMSO is 45 parts by weight, anesthetic is advantageously 4.0 parts by weight Lidocaine, Echinaceas is 1.0 part by weight and Arnica is 1.0 part by weight, and the condition causing pain of the foot is Plantar Fasciitis.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: August 18, 2020
    Inventors: Robert Alonso, Lawrence G. Stoll
  • Patent number: 10744175
    Abstract: Disclosed herein is a therapeutic herbal composition comprising extracts of herbs selected from Hypericum mysorense, Holoptelia integrifolia, Terminalia chebula, Glycyrrhiza glabra, Acacia Catechu, Rosa canina, Tecoma avellanedae, Olea europaea, Boswellia serratta and optionally comprises Asthaxantin along with pharmaceutical acceptable excipients, useful for the treatment of symptoms associated with Herpes simplex virus, Human papilloma virus and other viral infections. The invention further discloses a method of treating the Herpes simplex virus, Human papilloma virus and other viral infections by administering said therapeutic herbal composition to a subject in need thereof.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: August 18, 2020
    Inventor: Apurve Mehra
  • Patent number: 10744176
    Abstract: An edible orally disintegrating tablet dosage form containing an unpalatable acidic active pharmaceutical ingredient, particularly ketoprofen, and an ion exchange resin as a primary taste masking agent, along with an optional alkaline agent and further optionally containing one or more secondary taste masking agents is provided. The edible orally disintegrating tablet dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). The inventive dosages minimize or completely mask the bitterness, burning sensation and throat irritation associated with many acidic active pharmaceutical ingredients. Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: August 18, 2020
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Li, Markus Krumme
  • Patent number: 10744177
    Abstract: The present disclosure relates to compositions and therapeutic uses of Chardonnay grape product and other grape seed products. In one embodiment, the grape seed product is used to treat or prevent joint pain or inflammation or to maintain healthy joints. The grape seed product can be the defatted portion of Chardonnay seed, such as Chardonnay pomace meal, Chardonnay pomace flour, Chardonnay seed meal, or, in some embodiments, Chardonnay seed flour or seed extract. Such products can be administered as a food or beverage.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: August 18, 2020
    Assignee: SONOMACEUTICALS, LLC
    Inventor: Torey James Arvik
  • Patent number: 10744178
    Abstract: The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: August 18, 2020
    Assignee: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Patent number: 10744179
    Abstract: This invention relates to the use of an agent capable of inhibiting IL-36 proteolytic processing for the treatment and/or reduction of inflammation in a subject. Advantageously, the agent prevents the production of a biologically active IL-36 to prevent and/or reduce the pro-inflammatory effects of IL-36. The invention also relates to a method for treatment and/or reduction of inflammation and compositions for treating and/or reducing inflammation.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: August 18, 2020
    Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY
    Inventors: Seamus J. Martin, Conor Henry, Graeme Sullivan
  • Patent number: 10744180
    Abstract: Compositions, kits and methods for preventing or treating cystic fibrosis are provided, which include the use of a peptidomimetic that inhibits the interaction between CAL and mutant CFTR proteins.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 18, 2020
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Dean R. Madden, Nicholas P. Gill, Carrie Ann Davison, Mark R. Spaller
  • Patent number: 10744181
    Abstract: The present invention relates to a compound of the following formula (I), as well as to a pharmaceutical composition comprising at least one compound of following formula (I) and at least one pharmaceutically acceptable excipient, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: August 18, 2020
    Assignee: TFCHEM
    Inventors: Géraldine Deliencourt-Godefroy, Jocelyne Legoedec
  • Patent number: 10744182
    Abstract: A method of tolerance to narcotics in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin is selected from the group consisting of botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F and botulinum toxin type G, a fragment thereof, a hybrid thereof, a chimera thereof, and a combination thereof. The botulinum toxin may be administered by subcutaneous/intradermal injection. The subcutaneous/intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient. The therapeutically effective amount of the botulinum toxin administered is between about 1 unit and about 150 units.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: August 18, 2020
    Assignee: PENLAND FOUNDATION
    Inventor: Roland M. Williams
  • Patent number: 10744183
    Abstract: The present disclosure relates to methods for increasing telomere length in one or more human adult cells and/or increasing genome stability of one or more human adult cells, for example by contacting one or more human adult cells with an agent that increases expression of Zscan4 in the one or more human adult cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a telomere abnormality, of rejuvenating one or more human adult cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human adult cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 is also provided.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 18, 2020
    Assignee: Elixirgen Therapeutics, Inc.
    Inventor: Minoru S. H. Ko
  • Patent number: 10744184
    Abstract: Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 18, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mark E. Cook, Elizabeth A. Bobeck, Kimberly S. Burgess
  • Patent number: 10744185
    Abstract: Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FG-F19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 18, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo, Hui Tian
  • Patent number: 10744186
    Abstract: A method for treating cancer and/or preventing or reducing metastasis or treating angiogenesis related disorders comprising the step of administering IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 18, 2020
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Ella Fremder, Ami Aronheim, Yuval Shaked
  • Patent number: 10744187
    Abstract: An insulin conjugate having improved in vivo duration and stability is provided. The conjugate is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 18, 2020
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Hae Song, Jae Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
  • Patent number: 10744188
    Abstract: An improved manufacturing process produces microcrystalline hydroxyapatite with sustained gradual calcium release that avoids spiking in blood calcium levels. Although the improved material did not cause significant elevation of blood calcium, it was just as effective in promoting bone mineralization as conventional calcium supplements. In addition, the material has much higher levels of bone growth factors as compared to prior hydroxyapatite products.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: August 18, 2020
    Assignee: Waitaki Biosciences
    Inventors: Craig Lachlan McIntosh, Susan Finderup, Harold Garthwaite
  • Patent number: 10744189
    Abstract: The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 18, 2020
    Assignee: CONTRAFECT CORPORATION
    Inventors: Raymond Schuch, Simon Hoffenberg, Michael Wittekind
  • Patent number: 10744190
    Abstract: The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: August 18, 2020
    Assignee: IPSEN BIOINNOVATION LIMITED
    Inventors: John Andrew Chaddock, Keith Alan Foster
  • Patent number: 10744191
    Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: August 18, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Kalyani Mondal, Betty Chan Li, Yu Chen, Taruna Arora, Hugo Matern, Wenyan Shen
  • Patent number: 10744192
    Abstract: The invention is based upon the identification of a number of antigens derived from a species of the genus Streptococcus, which are cross reactive and which may serve as the basis of useful compositions and tests and procedures capable of identifying and/or detecting Streptococcus sp in samples.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 18, 2020
    Assignee: Moredun Research Institute
    Inventors: Michael Christopher Fontaine, David George Emslie Smith, Julie Lydia Fitzpatrick, William Donachie, Anita Dorota Jaglarz
  • Patent number: 10744193
    Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: August 18, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Surender Khurana, Hana Golding
  • Patent number: 10744194
    Abstract: Described herein are processes for purifying infectious Zika virus particles and uses of protamine in such processes.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: August 18, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario NebenfĂĽhr, Robert Schlegl, Michael Weber, JĂĽrgen Wruss
  • Patent number: 10744195
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: August 18, 2020
    Assignees: Altimmune Inc., Auburn University
    Inventors: De-Chu C. Tang, Kent R. Van Kampen, Haroldo Toro
  • Patent number: 10744196
    Abstract: The present invention relates to novel vaccines against Human papillomavirus (HPV) infections, based on recombinant capsid-display adenovirus vectors. Described are capsid modified replication deficient adenovirus particles encoding and displaying multiple HPV L2 antigenic fragments, via a minor capsid protein IX, and their use for eliciting an immune response in order to provide protection against infections from multiple HPV types.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: August 18, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Marija Vujadinovic, Taco Gilles Uil, Koen Oosterhuis, Jort Vellinga, JerĂ´me Hubertina Henricus Victor Custers
  • Patent number: 10744197
    Abstract: The present invention provides a vaccine pharmaceutical composition for oral administration that enables stable storage of an influenza virus antigen and a method for producing the pharmaceutical composition. Provided is a vaccine pharmaceutical composition for oral administration containing an influenza virus antigen, an excipient, a disaccharide, and an amino acid.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: August 18, 2020
    Assignee: NITTO DENKO CORPORATION
    Inventors: Takuya Shishido, Daisuke Asari, Eiji Kiyotoh, Kyohei Matsushita, Wenjing Li, Masahiro Fukasaka, Katsuyuki Okubo, Mitsuhiko Hori
  • Patent number: 10744198
    Abstract: Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites).
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 18, 2020
    Assignee: Najit Technologies, Inc.
    Inventors: Ian J. Amanna, Elizabeth A. Poore
  • Patent number: 10744199
    Abstract: Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: August 18, 2020
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Masaru Kanekiyo, Gary J. Nabel, Jeffrey Cohen, Wei Bu
  • Patent number: 10744200
    Abstract: The present invention relates to an improved process for production of Aluminium phosphate (AlPhos) gel wherein the solutions of aluminium salt and alkaline phosphate salt are added to water by maintaining the pH under stirring to obtain the precipitate, followed by sterilization of the said precipitate and finally obtaining the Aluminum phosphate gel.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: August 18, 2020
    Assignee: BIOLOGICAL E LIMITED
    Inventors: Ravi Ganapathy, Nagireddy Gade, Manish Manohar, Vikram Madhusadan Paradkar, Mahima Datla
  • Patent number: 10744201
    Abstract: A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is preferably an antibody to an interleukin-6 receptor (IL-6R).
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: August 18, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Osamu Okuda, Noriaki Yoshida, Ravinder Nath Maini
  • Patent number: 10744202
    Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: August 18, 2020
    Assignee: Ramscor, Inc.
    Inventors: Vernon G. Wong, Louis L. Wood
  • Patent number: 10744203
    Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3?, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: August 18, 2020
    Assignees: Purdue Research Foundation, University of Utah
    Inventors: Stewart Andrew Low, Philip S. Low, Christopher Galliford, Jindrich Kopecek, Jiyan Yang
  • Patent number: 10744204
    Abstract: This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: August 18, 2020
    Assignee: MedImmune, LLC
    Inventors: Changshou Gao, Godfrey Rainey, Cuihua Gao
  • Patent number: 10744205
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: August 18, 2020
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Beatrix Stelte-Ludwig, Christoph Mahlert, Simone Greven, Stephan Märsch, Dennis Kirchhoff
  • Patent number: 10744206
    Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: August 18, 2020
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Patent number: 10744207
    Abstract: The disclosure provides complexes comprising targeting units, methods for their production, and methods for their use. In some embodiments, complexes comprise therapeutic agents complexed with targeting units. In some embodiments, complexes comprise cells complexed with targeting units. In view of the foregoing, there is a need for improved modalities for targeting of therapeutics, in the area of immunotherapy and others. The present disclosure addresses these needs, and provides additional advantages as well.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: August 18, 2020
    Assignee: ACEPODIA, INC.
    Inventors: Amy A. Twite, Ching-Wen Hsiao, Sonny Hsiao, Cheng Liu, Hong Liu
  • Patent number: 10744208
    Abstract: A method of killing cells of a targeted cell type in a patient body that utilizes nanoparticles (10) having a first portion (12), which when exposed to a target portion (14) of a targeted cell type (16), binds to the target portion and a second portion (10A), joined to the first portion, and comprised of a low resistivity material. The nanoparticles are introduced into a contact area where they contact cells of the targeted cell type. Contemporaneously, the contact area is exposed to a varying magnetic field of insufficient strength to increase the temperature of any part of the patient body by more than ten degrees Celsius, but which creates a current (20) at the nanoparticles sufficient to disrupt function of the targeted cell type.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: August 18, 2020
    Inventor: Robert E. Sandstrom
  • Patent number: 10744209
    Abstract: The present invention relates to a polymeric nanoparticle conjugate of formula (I). The present invention also relates to pharmaceutical compositions including these polymeric nanoparticle conjugates, and methods of preparation and use thereof.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: August 18, 2020
    Assignee: NEW YORK UNIVERSITY
    Inventors: Abraham Ulman, Bruce Cronstein, Linda Franks
  • Patent number: 10744210
    Abstract: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention provides a method to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene. The viral vector delivers the transgene to a region of the deep cerebellar nuclei region of the brain. Also provided are compositions and methods to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene to the motor cortex region of the subject's brain.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: August 18, 2020
    Assignee: GENZYME CORPORATION
    Inventors: James Dodge, Lamya Shihabuddin, Marco Passini, Seng H. Cheng, Catherine O'Riordan
  • Patent number: 10744211
    Abstract: The invention provides a novel trifunctional targeting construct and related compositions and methods that are useful in therapeutic, diagnostic (including imaging) of various biological and/or pathological conditions and diseases such as cancers and diabetes. The trifunctional targeting construct of the invention provides enhanced clearing step and reduced non-specific background via complete clearance of undesired antibody conjugates.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: August 18, 2020
    Assignee: University of Massachusetts
    Inventors: Guozheng Liu, Shuping Dou
  • Patent number: 10744212
    Abstract: The present invention relates to a topical agent that binds specifically to myelin basic protein and its method of use and determining myelination in the subject by detecting the agent present in the subject. A kit containing the agent or its derivatives for use in detecting myelin basic protein is also provided.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: August 18, 2020
    Assignee: GENERAL ELECTRIC COMPANY
    Inventors: Cristina Abucay Tan Hehir, Tiberiu Mircea Siclovan, Victoria Eugenia Cotero
  • Patent number: 10744213
    Abstract: The present invention discloses fluorescent compounds and a method for their use for selective imaging of blood vessels and blood flow. By applying these fluorescent compounds and the imaging process to a zebrafish model, the present invention further provides methods and procedures for the discovery, selection, and characterization of pro- and anti-angiogenic agents.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: August 18, 2020
    Assignee: COLOSSUS BIOPHARMA CONSULTANTS COMPANY, LIMITED
    Inventor: Jose Mendoza
  • Patent number: 10744214
    Abstract: The present invention is directed to novel non-invasive diagnostic took to dispose numerous disease states and/or conditions. The presets invention, represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. The methods described herein are able to diagnose, treat and/or monitor the therapy of numerous diseases and conditions including atherosclerosis, atherothrombosis, cerebral vascular disease, cerebral ischemia, cerebral infarct and meningitis as well as pneumonitis, pericarditis, multiple sclerosis, lupus erythematosus and pancreatitis, among others.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: August 18, 2020
    Assignee: STC.UNM
    Inventor: Jeffrey P. Norenberg
  • Patent number: 10744215
    Abstract: A sanitization device comprises an enclosure comprising emitters configured to emit sanitizing electro-optical radiation into an interior compartment. The sanitization device further includes a panel having an open configuration and a closed configuration adapted to enclose the inner compartment. The panel includes an inner surface forming a depression configured to receive a portable device when the panel is in the open configuration and to secure the portable device as the panel transitions to the closed configuration. The sanitization device may further comprise an actuator configured to transition the panel between the open and closed configurations in response to inputs received via a touchless input interface.
    Type: Grant
    Filed: September 14, 2019
    Date of Patent: August 18, 2020
    Assignee: Phonesoap LLC
    Inventors: Wesley LaPorte, Daniel Barnes
  • Patent number: 10744216
    Abstract: A fluid sterilization device includes: a processing flow passage in which a fluid subject to sterilization flows; a window member provided between a light source for irradiating the fluid in the processing flow passage with ultraviolet light and the processing flow passage, the window member including an incidence surface on which the ultraviolet light from the light source is incident and an exit surface from which the ultraviolet light exits toward the processing flow passage; and a heating body provided to be in contact with the incidence surface and adapted to heat the window member.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: August 18, 2020
    Assignee: NIKKISO CO., LTD.
    Inventors: Shoichi Niizeki, Kenta Ura
  • Patent number: 10744217
    Abstract: A device a method, and a computer program for use in a device (40) for washing, disinfecting and/or sterilizing medical, dental, laboratory and/or pharmaceutical goods. The device comprises a chamber (41) for receiving the goods, a door (42) associated with the chamber (41) and a processing circuitry for creating and storing a track record of at least one parameter of the washing, disinfecting and/or sterilizing process performed by the device (40). The user interface (44, 45) is operable by the user to cause the process circuitry to electronically sign the track record, and wherein the signing of the track record is associated with at least one condition on the device (40). The device, method and computer program facilitates an easy and secure signing of a track record directly on the device.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: August 18, 2020
    Assignee: GETINGE STERILIZATION AB
    Inventors: Jonas Andersson, Per Norlin
  • Patent number: 10744218
    Abstract: A holder device for holding a plurality of tonometer tips or the like during a disinfection procedure has a top wall, spaced rims extending downward from the top wall to engage a support surface and hold the top wall above the support surface, and handle portions extending upwards from the top wall. The top wall has a plurality of spaced holes of predetermined diameter each configured to hold a tip extending partially through the hole with a lower end of the tip spaced above a support surface. A cover plate is releasably secured between the handle portions at a location spaced above the top wall after loading the holes with tips, and holds the tips in the holes while at least a major portion of the device is submerged in a bath of disinfectant.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: August 18, 2020
    Assignee: United States Government as Represented by the Department of Veterans Affairs
    Inventors: Richard A. Stein, Kelly R. Foudray
  • Patent number: 10744219
    Abstract: The present invention relates to the field of air cleaning, and specifically discloses an air freshener composition. The air freshener composition comprises component A and component B, wherein a weight ratio of the component A to the component B is 1:0.5-3; the component A comprises, in parts by weight, 10-30 parts by weight of an active agent; 6-15 parts by weight of a carrier; 1-4 parts by weight of a pH regulator; and 0.01-0.2 part by weight of an antioxidant; the component B is a plant extract solution, wherein the plant extract solution comprises at least, in parts by weight: 5-30 parts by weight of an extract of a mixture of Populus nigra var. italica, grapefruit peels and eucalyptus leaves; 0.1-5 parts by weight of Sophora flavescens extract; 1-3 parts by weight of Aloe vera extract; 1-10 parts by weight of fresh orange peel extract; 0.5-3 parts by weight of Nandina domestica extract; 0.5-10 parts by weight of Eucalyptus robusta Smith extract; 1-8 parts by weight of Robinia pseudoacacia L.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: August 18, 2020
    Assignee: GUORUN BIOTECHNOLOGY (SHENZHEN) CO., LTD.
    Inventor: Jingning Wang
  • Patent number: 10744220
    Abstract: An apparatus for removing air pollutants from the air is described. The apparatus contains a fan module and a chamber that can hold either activated carbon or a gel that reacts with air pollutants from air.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: August 18, 2020
    Assignee: Honeywell International Inc.
    Inventors: Kai Huang, Marilyn Wang, Xingping Wang, Wesley Nie, Hailin Liu
  • Patent number: 10744221
    Abstract: An air scenting assembly includes: a scent container which at least initially contains a scent perfume, and a scent perfume extracting mechanism, which is configured to release scent perfume from the scent container.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 18, 2020
    Assignee: COMMON SENSE HOLDING B.V.
    Inventor: Ewoud Kees Kuijper
  • Patent number: 10744222
    Abstract: A fragrance dispenser for emitting fragrance into an airstream impinging on an air filter, the dispenser having a receptacle with an open end that faces toward the air filter and that has a porous diffuser layer occlusively overlying the open end of the receptacle.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: August 18, 2020
    Assignee: 3M Innovative Properties Company
    Inventors: Kannan Seshadri, Neeraj Sharma, Le'Bron K. Patterson, Jeffrey M. Imsande, Nicolas A. Echeverri, Joon Chatterjee
  • Patent number: 10744223
    Abstract: Disclosed are scented material compositions, articles and methods of their manufacture. In some aspects, a scented attachment for a beverage container includes a scented article including a body loaded with a volatile chemical compound to emanate from the body of the scented article to generate a scent, in which the scented article includes at least one interior protruding structure that projects from an interior wall of the body of the scented article and is configured to attach to a bottle and be enclosed by a cap and the bottle when the cap is securely fastened to the bottle, such that the scent from the scented attachment is trapped when the cap is securely attached to the bottle and releases into an outer environment when the cap is detached from the bottle, in which the scented article comprises a scented material formed of a fragrance oil and a plastic base material.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: August 18, 2020
    Assignee: SZENT CO.
    Inventor: Shawn Griffis